课题基金 / 基金详情

Identification of Causal Antigens in Immune Checkpoint Inhibitor-Induced Myocarditis

Identification of Causal Antigens in Immune Checkpoint Inhibitor-Induced Myocarditis
免疫检查点抑制剂诱发的心肌炎的致病抗原的鉴定
批准号:
10022140
负责人:
Han Zhu
金额:
$1.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-14 至 2020-10-30
关键词:
AcuteAdjuvant TherapyAdvanced Malignant NeoplasmAdverse drug effectAffectAgeAlgorithmsAnimalsAntibodiesAntibody Binding SitesAntigen-Antibody ComplexAntigensArrhythmiaAtherosclerosisAutoantigensAutoimmune DiseasesAutoimmune ProcessAutopsyBiologicalBiopsyBloodCD8-Positive T-LymphocytesCancer PatientCardiacCardiac DeathCardiotoxicityCardiovascular DiseasesCardiovascular systemCellsCessation of lifeClinicalClonal ExpansionClone CellsComputational algorithmCytometryCytotoxic T-LymphocytesDNA sequencingDatabasesDevelopmentDiseaseEnsureEpitopesFlow CytometryGoalsGroupingHeartHeart failureHistopathologyHumanImmuneImmune checkpoint inhibitorImmune responseImmunohistochemistryImmunologicsImmunophenotypingInfiltrationInflammationInflammatoryKnock-outKnowledgeLeadLifeLightLymphocyteLymphocytic InfiltrateMalignant NeoplasmsMediatingMentorsMetastatic MelanomaMethodsMonoclonal AntibodiesMusMyocardialMyocarditisMyocardiumNon-Small-Cell Lung CarcinomaPathologicPatientsPeripheral Blood Mononuclear CellPhenotypePhysiciansPlayPopulationPreventionProcessReactionRegulatory PathwayReportingRoleSafetySamplingScientistSiteSpecificityT-Cell ActivationT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTechniquesTestingTherapeuticTissuesTrainingVariantage groupcell typecheckpoint therapycohortcross reactivitycytokinecytotoxicityheart damageinsightlupus-likemouse modelmyocardial damageneoplastic cellnew therapeutic targetnovelprogrammed cell death ligand 1programmed cell death protein 1responseside effectsudden cardiac deathtime use

项目摘要

项目成果

Han Zhu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Myocarditis, pathologic inflammation of the heart, is a serious cause of sudden cardiac death affecting patients of all age groups. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies to cytotoxic T-cell antigen-4 (CTLA-4) or programmed death-1 (PD-1)/programmed death-1 ligand (PD-1L) used as novel cancer therapeutics to release intrinsic brakes on T-cell cytotoxicity against tumor cells. Although ICIs are now relied upon to treat many advanced cancers, fulminant myocarditis has been reported as a life-threatening side effect of these drugs, leading to severe arrhythmias, heart failure and death. Under histopathology, an acute lymphocytic infiltrate is found in the heart, and multiple lines of evidence point to a T-cell and antigen-mediated phenomenon. Although T-cell clonal analysis of patient heart tissues suggest the existence of a cardiac-specific antigen in ICI-induced myocarditis, the identity of such antigen(s) remains elusive. Understanding the culprit antigens in this disease may lead to novel insights on the mechanism of T-cell mediated myocardial damage. I hypothesize that ICI-induced myocarditis is an autoimmune disorder caused by cardiac-specific auto- antigens that trigger the activation and clonal expansion of T-cells, leading to myocardial inflammation. The goal of this study is to use an advanced immunophenotyping technique called CyTOF to characterize T-cell subsets, and then use single-cell T-cell receptor sequencing and a novel computational algorithm called GLIPH (Grouping Lymphocyte Interactions by Paratope Hotspots) to identify specific epitopes responsible for T-cell activation in ICI- induced myocardial damage in mice and humans. By completing this project, I will uncover key insights into the biological mechanism of ICI-induced myocarditis which will bridge a major knowledge gap regarding the role of T-cells in mediating myocardial damage. My results will answer the key question of which immune cell types play a dominant role in ICI-induced myocarditis, as well as identify disease-causing antigens causing cardiotoxicity. There is increasing evidence to suggest that immune-mediated cardiac damage may be at the heart of many major cardiovascular diseases, ranging from autoimmune myocarditis to heart failure to atherosclerosis. My long-term goal as a physician-scientist is to elucidate mechanisms of pathological inflammation in the heart to help cure cardiovascular disease and become a leader in the field of cardiac inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
  • 批准号:
    10351289
  • 项目类别:
  • 资助金额:
    $16.63万
  • 财政年份:
    2022
  • 负责人:
    Han Zhu
  • 依托单位:
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
  • 批准号:
    10545278
  • 项目类别:
  • 资助金额:
    $16.63万
  • 财政年份:
    2022
  • 负责人:
    Han Zhu
  • 依托单位:
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
  • 批准号:
    10712007
  • 项目类别:
  • 资助金额:
    $4.84万
  • 财政年份:
    2022
  • 负责人:
    Han Zhu
  • 依托单位:
海外基金